公开(公告)号：US20230137861A1

公开(公告)日：2023-05-04

申请号：US17907791

申请日：2021-02-24

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hoon HUR ,  In-hye HAM ,  Dagyeong LEE

IPC: C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to: a biomarker composition for diagnosing diffuse type gastric cancer, containing, as an active ingredient, a TINAGL1 protein or a gene encoding the protein; and a medical use thereof. More specifically, it is ascertained that: the secretion of TINAGL1 increases in cancer-associated fibroblasts separated from a diffuse type gastric cancer tissue; TINAGL1 improves metastasis and tumor formation of diffuse type gastric cancer by activating FAK signaling of cancer cells; the increase in TINAGL1 expression is related to the prognosis of a diffuse type gastric cancer patient. Therefore, TINAGL1 can be provided as a biomarker for the diagnosis and prognosis prediction of diffuse type gastric cancer, and a TINAGL1 expression or activity inhibitor can be provided as an effective agent for treating diffuse type gastric cancer.